Royce & Associates LP Veracyte, Inc. Transaction History

Royce & Associates LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$32.49 - $61.88 $1.3 Million - $2.48 Million	-40,150 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$19.49 - $28.11 $993,989 - $1.43 Million	-51,000 Reduced 55.95%	40,150 $1.04 Million
Q4 2019 Feb 06, 2020	SELL	$20.78 - $29.99 $1.16 Million - $1.68 Million	-56,000 Reduced 38.06%	91,150 $2.55 Million
Q3 2019 Nov 13, 2019	SELL	$23.87 - $30.93 $596,750 - $773,250	-25,000 Reduced 14.52%	147,150 $3.53 Million
Q2 2019 Aug 12, 2019	SELL	$22.1 - $28.56 $1.66 Million - $2.14 Million	-75,000 Reduced 30.35%	172,150 $4.91 Million
Q3 2018 Nov 13, 2018	BUY	$9.55 - $12.64 $1.64 Million - $2.18 Million	172,150 Added 229.53%	247,150 $2.36 Million
Q2 2018 Aug 09, 2018	BUY	$5.39 - $9.66 $404,250 - $724,500	75,000 New	75,000 $701,000

339

80.4M

212K

18.5K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.27B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.